Eugeni Lopez-Bonet, Maria Buxó, Elisabet Cuyàs, Sonia Pernas, Joan Dorca, Isabel Álvarez, Susana Martínez, Jose Manuel Pérez-Garcia, Norberto Batista-López, César A Rodríguez-Sánchez, Kepa Amillano, Severina Domínguez, Maria Luque, Idoia Morilla, Agostina Stradella, Gemma Viñas, Javier Cortés, Gloria Oliveras, Cristina Meléndez, Laura Castillo, Sara Verdura, Joan Brunet, Jorge Joven, Margarita Garcia, Samiha Saidani, Begoña Martin-Castillo, Javier A Menendez
The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tumor recurrence. We explored the therapeutic potential of adding neoadjuvant metformin as an innovative strategy to decrease the proliferative potential of residual BC cells in patients failing to achieve pathological complete response (pCR) after pre-operative therapy. We performed a prospective analysis involving the intention-to-treat population of the (Metformin and Trastuzumab in Neoadjuvancy) METTEN study, a randomized multicenter phase II trial of women with primary, non-metastatic (human epidermal growth factor receptor 2) HER2-positive BC evaluating the efficacy, tolerability, and safety of oral metformin (850 mg twice-daily) for 24 weeks combined with anthracycline/taxane-based chemotherapy and trastuzumab (arm A) or equivalent regimen without metformin (arm B), before surgery...
December 11, 2019: Journal of Clinical Medicine